Date | Title | Description | Source |
27.06.2023 | ContraFect Enters Into a Warrant Exercise Transaction for Pr... | /EIN News/ -- YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX)... | einpresswi... |
08.06.2023 | ContraFect to Present New Data Demonstrating the Potential E... | /EIN News/ -- YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX)... | einpresswi... |
28.11.2022 | ContraFect Announces ANSM Approval of Clinical Trial Applica... | /EIN News/ -- YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX)... | einpresswi... |
12.09.2022 | ContraFect Announces Presentation of New Clinical Data From ... | YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-... | globenewsw... |
12.09.2022 | ContraFect Announces Multiple Publications Highlighting the ... | YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-... | globenewsw... |
15.08.2022 | ContraFect Reports Second Quarter 2022 Financial Results and... | YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-s... | globenewsw... |
15.08.2022 | ContraFect Announces Publication on Exebacase and CF-296 Dem... | YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-s... | globenewsw... |
14.07.2022 | Updated: ContraFect to terminate PhIII MRSA antibi... | One year after BARDA backed ContraFect’s MRSA treatment, the Yonkers, NY-based biotech said We... | endpts.com... |
13.07.2022 | ContraFect Announces Independent DSMB Recommends Exebacase P... | YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a biotechnol... | globenewsw... |
14.06.2022 | Presentations at ASM Microbe Conference Demonstrate Potentia... | YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
06.06.2022 | ContraFect to Present Data Demonstrating the Potential of It... | YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
20.05.2022 | ContraFect Announces Inducement Grants Under Nasdaq Listing ... | YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), ... | globenewsw... |
16.05.2022 | ContraFect Reports First Quarter 2022 Financial Results and ... | YONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinic... | globenewsw... |
27.04.2022 | ContraFect Data Presentations at the 32nd Annual ECCMID Meet... | YONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clin... | globenewsw... |
18.04.2022 | ContraFect Announces Multiple Presentations of New Data Demo... | YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clin... | globenewsw... |
24.03.2022 | ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Fi... | YONKERS, N.Y., March 24, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clin... | globenewsw... |
21.03.2022 | ContraFect to Present at the Maxim Group 2022 Virtual Growth... | YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clin... | globenewsw... |
10.02.2022 | ContraFect to Present at the SVB Leerink 11th Annual Global ... | YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
10.02.2022 | ContraFect to Present at the SVB Leerink 11th Annual Global ... | YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
07.01.2022 | ContraFect Announces Award from the Cystic Fibrosis Foundati... | YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
06.01.2022 | ContraFect Announces Award from the Cystic Fibrosis Foundati... | YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
20.12.2021 | Compassionate Use Case Study Demonstrating the Potential of ... | YONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
20.12.2021 | Compassionate Use Case Study Demonstrating the Potential of ... | YONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
15.11.2021 | ContraFect Reports Third Quarter 2021 Financial Results and ... | YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
15.11.2021 | ContraFect Reports Third Quarter 2021 Financial Results and ... | YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
09.11.2021 | ContraFect’s New Data Presented at NACFC Demonstrate Potenti... | YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
09.11.2021 | ContraFect's New Data Presented at NACFC Demonstrate Potenti... | YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
26.10.2021 | ContraFect to Present Data on the Potential of DLAs to Treat... | YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
26.10.2021 | ContraFect to Present Data on the Potential of DLAs to Treat... | YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | globenewsw... |
04.10.2021 | ContraFect : New Phase 2 Exebacase Data Presented at IDWeekT... | YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late cl... | marketscre... |
29.09.2021 | ContraFect to Present New Late Breaking Phase 2 Exebacase Da... | Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding ... | marketscre... |
22.09.2021 | ContraFect Corporation : to Present at the 2021 Cantor Globa... | YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clin... | marketscre... |
19.07.2021 | ContraFect : Announces Multiple Publications on CF-296 Demon... | YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
19.07.2021 | ContraFect : Announces Multiple Presentations of New Researc... | YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clini... | marketscre... |
26.05.2021 | CONTRAFECT CORPORATION
ContraFect Announces Multiple Public... | Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee inf... | marketscre... |
03.05.2021 | CONTRAFECT CORPORATION
ContraFect Announces Issuance of Com... | YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinic... | marketscre... |
30.03.2021 | CONTRAFECT CORPORATION
ContraFect Reports Fourth Quarter an... | Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infecti... | marketscre... |
11.03.2021 | ContraFect Announces BARDA Contract Award for Up to $86.8 Mi... | BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of pat... | globenewsw... |
11.02.2021 | ContraFect Announces Appointment of Dr. Jane F. Barlow to Bo... | YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-st... | globenewsw... |
04.03.2019 | ContraFect Announces $6.94M In Funding From CARB-X | YONKERS, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-s... | citybizlis... |
17.01.2019 | ContraFect Announces Additional $2.3M In Funding From CARB-X | YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-st... | citybizlis... |
06.10.2017 | David Meeker starts a new biotech chapter in his career; ... | → David Meeker left Genzyme last April after a 23-year run, including six years as president ... | endpts.com... |
30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Ac... | medcitynew... |
26.10.2010 | ContraFect Raises $14.4M in Two Financing Rounds | ContraFect Corporation, a New York, NY-based biotechnology company that is pioneering the use of mon... | finsmes.co... |
- | CARB-X dishes out $48M in grants to antimicrobial startups | CARB-X is making it rain.
The international antimicrobial consortium today announced grants totalin... | medcitynew... |